INS and type 2 diabetes mellitus: Addition of vildagliptin to insulin therapy has been found to be associated with severe hypoglycemia.[19] During meal tolerance test, single dose of vildagliptin augments insulin secretion in T2DM patients and inhibits hepatic glucose release, leading to increased suppression of endogenous glucose production (EGP).